Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
- Conditions
- Leptomeningeal MetastasisNSCLCPD-1 InhibitorLow Dose Radiotherapy
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 10
- Registration Number
- NCT06431685
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 630
- Registration Number
- NCT06417814
- Locations
- 🇻🇳
Research Site, Hanoi, Vietnam
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- Conditions
- Advanced Non-squamous Non-small-cell Lung CancerMetastatic Non-squamous Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Allist Pharmaceuticals, Inc.
- Target Recruit Count
- 392
- Registration Number
- NCT06416410
- Locations
- 🇨🇳
Anhui Province cancer hospital, Hefei, Anhui, China
🇨🇳Pecking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, Beijing, China
A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
- Conditions
- First-line Advanced NSCLC Patients
- Interventions
- Drug: Paclitaxel-albuminDrug: PD-1/L1
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-07-30
- Target Recruit Count
- 235
- Registration Number
- NCT06412471
- Locations
- 🇨🇳
Institute of The Hunan Cancer Hospital, Changsha, China
Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
- Conditions
- Leptomeningeal MetastasisLung Cancer
- Interventions
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 64
- Registration Number
- NCT06399926
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer
- Conditions
- Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer
- Interventions
- Radiation: Stereotactic radiotherapyDrug: Evoximab
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Target Recruit Count
- 44
- Registration Number
- NCT06391008
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- Conditions
- Advanced KRAS G12D Mutant Solid Tumors
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT06385678
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
- Conditions
- Local Advanced or Metastatic NSCLC
- Interventions
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 398
- Registration Number
- NCT06380348
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 24
- Registration Number
- NCT06364917
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer
- Conditions
- Non-small-cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 30
- Registration Number
- NCT06357598
- Locations
- 🇨🇳
the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.